Alterity Therapeutics Stock Performance
| ATHE Stock | USD 3.30 0.07 2.08% |
The firm shows a Beta (market volatility) of 1.96, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Alterity Therapeutics will likely underperform. At this point, Alterity Therapeutics has a negative expected return of -0.0571%. Please make sure to confirm Alterity Therapeutics' accumulation distribution, and the relationship between the potential upside and day median price , to decide if Alterity Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Alterity Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound technical indicators, Alterity Therapeutics is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Actual Historical Performance (%)
One Day Return (2.02) | Five Day Return (6.52) | Year To Date Return 4.43 | Ten Year Return (91.13) | All Time Return (99.51) |
Last Split Factor 1:10 | Last Split Date 2023-01-09 |
1 | Will Alterity Therapeutics Limited stock outperform foreign stocks - 2025 Stock Rankings Consistent Profit Alerts - Newser | 12/03/2025 |
2 | I backpacked across Europe for 2 weeks. Here are the best things I packed and the items I wished Id left at home. | 12/26/2025 |
3 | Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026 | 01/21/2026 |
4 | COLM Q4 Deep Dive International Momentum and Brand Strategy Offset U.S. Headwinds | 02/04/2026 |
| Begin Period Cash Flow | 12.6 M | |
| Total Cashflows From Investing Activities | -7.5 M | |
| Free Cash Flow | -11.5 M |
Alterity Therapeutics Relative Risk vs. Return Landscape
If you would invest 355.00 in Alterity Therapeutics on November 23, 2025 and sell it today you would lose (25.00) from holding Alterity Therapeutics or give up 7.04% of portfolio value over 90 days. Alterity Therapeutics is currently does not generate positive expected returns and assumes 3.6312% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Alterity, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Alterity Therapeutics Target Price Odds to finish over Current Price
The tendency of Alterity Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 3.30 | 90 days | 3.30 | about 59.41 |
Based on a normal probability distribution, the odds of Alterity Therapeutics to move above the current price in 90 days from now is about 59.41 (This Alterity Therapeutics probability density function shows the probability of Alterity Stock to fall within a particular range of prices over 90 days) .
Alterity Therapeutics Price Density |
| Price |
Predictive Modules for Alterity Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Alterity Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Alterity Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Alterity Therapeutics is not an exception. The market had few large corrections towards the Alterity Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Alterity Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Alterity Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.32 | |
β | Beta against Dow Jones | 1.96 | |
σ | Overall volatility | 0.21 | |
Ir | Information ratio | -0.07 |
Alterity Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Alterity Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Alterity Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Alterity Therapeutics generated a negative expected return over the last 90 days | |
| Alterity Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 5.44 M. Net Loss for the year was (12.15 M) with profit before overhead, payroll, taxes, and interest of 5.31 M. | |
| Alterity Therapeutics currently holds about 34.81 M in cash with (11.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.87. | |
| Alterity Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Evaxion AS Coverage Initiated by Analysts at Maxim Group |
Alterity Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Alterity Stock often depends not only on the future outlook of the current and potential Alterity Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Alterity Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 10.7 M | |
| Cash And Short Term Investments | 40.7 M |
Alterity Therapeutics Fundamentals Growth
Alterity Stock prices reflect investors' perceptions of the future prospects and financial health of Alterity Therapeutics, and Alterity Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Alterity Stock performance.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.28 | ||||
| Profit Margin | (2.23) % | ||||
| Operating Margin | (1.86) % | ||||
| Current Valuation | 32.95 M | ||||
| Shares Outstanding | 18.13 M | ||||
| Price To Earning | (4.84) X | ||||
| Price To Book | 2.09 X | ||||
| Price To Sales | 11.00 X | ||||
| Revenue | 5.44 M | ||||
| Gross Profit | 5.31 M | ||||
| EBITDA | (14.63 M) | ||||
| Net Income | (12.15 M) | ||||
| Cash And Equivalents | 34.81 M | ||||
| Cash Per Share | 0.87 X | ||||
| Total Debt | 155.46 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 7.07 X | ||||
| Book Value Per Share | 0 X | ||||
| Cash Flow From Operations | (11.45 M) | ||||
| Earnings Per Share | (0.59) X | ||||
| Market Capitalization | 59.81 M | ||||
| Total Asset | 46.03 M | ||||
| Retained Earnings | (225.89 M) | ||||
| Working Capital | 42.34 M | ||||
| Current Asset | 14.26 M | ||||
| Current Liabilities | 1.73 M | ||||
About Alterity Therapeutics Performance
By analyzing Alterity Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Alterity Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Alterity Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Alterity Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.7 K | 2.2 K | |
| Return On Tangible Assets | (0.24) | (0.25) | |
| Return On Capital Employed | (0.39) | (0.41) | |
| Return On Assets | (0.30) | (0.32) | |
| Return On Equity | (0.33) | (0.35) |
Things to note about Alterity Therapeutics performance evaluation
Checking the ongoing alerts about Alterity Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Alterity Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Alterity Therapeutics generated a negative expected return over the last 90 days | |
| Alterity Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 5.44 M. Net Loss for the year was (12.15 M) with profit before overhead, payroll, taxes, and interest of 5.31 M. | |
| Alterity Therapeutics currently holds about 34.81 M in cash with (11.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.87. | |
| Alterity Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Evaxion AS Coverage Initiated by Analysts at Maxim Group |
- Analyzing Alterity Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Alterity Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Alterity Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Alterity Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Alterity Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Alterity Therapeutics' stock. These opinions can provide insight into Alterity Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Alterity Stock analysis
When running Alterity Therapeutics' price analysis, check to measure Alterity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alterity Therapeutics is operating at the current time. Most of Alterity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alterity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alterity Therapeutics' price. Additionally, you may evaluate how the addition of Alterity Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |